Background: For more than five decades, the Fontan or Fontan-Kreutzer procedure has been the mainstay treatment for congenital heart disease with a single functioning ventricle. Data concerning epidemiological profiles are poor, especially in countries with limited resources. Here, we present the cases of children with complex congenital heart disease (CHD) born in Kosovo who underwent some forms of Fontan palliation measuring the renal resistive index (RRI) to assess ventricular function and renal complications after the Fontan procedure. Objectives: This study aimed to describe the primary pathology, age, place of surgical intervention, and outcomes of children in Kosovo, a country with limited resources, who underwent the Fontan procedure in different countries. Results: from January 2018 to December 2021, 40 patients (28 male and 12 female) aged 6 to 19 years (mean 6.03 years) after a total Cavo-pulmonary connection were examined for renal insufficiency and thrombotic complications. The renal resistive index (RRI) and hematological parameters were analyzed as criteria for possible early and late complications. Two patients only developed complications in the cohort group. In both cases, the second and third stages of surgery were performed late, at the ages of 12 and 9 years. The first patient manifested a severe form of protein-lousing enteropathy, renal insufficiency, and plastic bronchitis, while the other patient presented with initial signs of protein-lousing enteropathy and recurrent ventricular tachycardia. Conclusion: Survival after Fontan operation in our group was excellent. Survival is closely dependent on the primary diagnosis, associated anomalies, age at palliation, and place of surgery
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium in which a portion of the myocardium is hypertrophied (thickened) without any obvious cause, creating functional impairment of the cardiac muscle. It is a leading cause of sudden cardiac death in young athletes. The occurrence of HCM is a significant cause of sudden unexpected cardiac death in any age group and as a cause of disabling cardiac symptom. AIM: The aim of the study was identification of the manifestations, assessment, and follows-up of children with HCM by transthoracic echocardiography as an important tool for clinical management and better understanding of pathogenesis of HCM. MATERIALS AND METHODS: We present a comprehensive analysis of 43 patients seen in Kosovo, with clinical and echocardiographic signs of HCM. Retrospectively, we analyzed medical records, treatment, and outcomes of those children, who have continued follow-up at our institution. RESULTS: Twenty-three of them were male, aged between 4 months and 9 years at the first presentation (median of 2 years and 3 months). Cardiac failure, seen in almost half of them, was the most frequent presenting feature. At admission, the chest radiographs revealed an increased cardiothoracic ratio, to a mean of 72% in 5 infants and to 65% in 37 older children. Measured by transthoracic echocardiography, 28 patients had asymmetric hypertrophy of the left ventricle while 15 had concentric hypertrophy. The left ventricular ejection fraction was depressed in 21 patients. Patients with cardiac failure received various combinations of diuretics, B-blockers, angiotensin-converting enzyme inhibitors, and aspirin. Death occurred in 8 patients, in 4 of them shortly after admission; 4 patients left Kosovo and continued examination abroad, and the remaining 32 were followed up for a mean 42 months, with a range from 5 to 115 months. Surgical intervention was not performed on any of them despite the clinical and echocardiographic indications. Recovery was noted in 14 patients but requiring anti-failure medications. Slightly over two-fifths died. Of those with asymmetric form, 45% died, in half of those presenting in infancy, and 89% of those who presented at admission with signs of cardiac failure. CONCLUSION: With the exception of the studies of pacing, no conclusive evaluations of treatments for HCM have been conducted. Management strategy is, therefore, based largely on clinical experience and consensus of many specialists.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.